SENTHORIS at Global Health Exhibition 2025 — Where AI Meets Human Health
Riyadh Exhibition & Convention Centre | Booth 27 |
27–30 October 2025
Imagine: health assessed in 15 seconds — through the eyes. No samples. No pain. No delay.
SENTHORIS is an AI-powered digital health platform redefining how the world detects psychoactive effects and early neuro-metabolic risks — through the pupil response.
Clinically grounded and validated in the industrial and transport sectors, SENTHORIS now scales this innovation globally.
Company profile - Let's meet up! 27–30 October 2025
Imagine: health assessed in 15 seconds — through the eyes. No samples. No pain. No delay.
SENTHORIS is an AI-powered digital health platform redefining how the world detects psychoactive effects and early neuro-metabolic risks — through the pupil response.
Clinically grounded and validated in the industrial and transport sectors, SENTHORIS now scales this innovation globally.
VISION 2030
and SENTHORIS
VISION 2030
and SENTHORIS
At the Global Health Exhibition in Riyadh, SENTHORIS is presenting a technology in the field of medical screening based on artificial intelligence — ecosystem that determines psychoactive effects based on pupil response in less than 15 seconds.
Our mission is to build a future-ready healthcare system, enhance public safety, and drive innovation through data sovereignty and strategic partnerships. Contribute to the path of a leader who sends signals to the whole World.
Our goal during GHE2025 is to find strategic partners in the GCC to scale the technology, regional localisation and investment within the Kingdom's Vision 2030 in the areas of healthcare and quality of life, artificial intelligence and national security.
How Does it Work?
The pupil is a direct mirror of the nervous system. Any change in light, emotion, or chemical state triggers a microscopic and precisely coordinated reaction — constriction or dilation — controlled by the brain’s autonomic centers.
Dynamic pupillometry captures this reaction with millisecond precision. A camera records the pupil’s movement under controlled light stimuli, while a trained AI/ML algorithm analyzes hundreds of parameters: speed, amplitude, asymmetry, reaction latency, and micro-oscillations. From this, a unique neurophysiological “fingerprint” of the body’s condition is formed.
Dynamic pupillometry captures this reaction with millisecond precision. A camera records the pupil’s movement under controlled light stimuli, while a trained AI/ML algorithm analyzes hundreds of parameters: speed, amplitude, asymmetry, reaction latency, and micro-oscillations. From this, a unique neurophysiological “fingerprint” of the body’s condition is formed.
Previously, such measurements were almost impossible: a doctor could only observe or roughly assess the reaction visually.
Our algorithms detect what the human eye cannot see — minimal deviations, hidden patterns, and dynamics at the level of thousandths of a second.
SENTHORIS uses this data to identify objective biomarkers related to neuro-autonomic, metabolic, or toxic processes.
This is pure science — a clinically proven technology, engineering precision, and a mathematical model that transforms the smallest movements of the pupil into a reliable source of information about human health.
Accuracy Evolution
Our algorithms detect what the human eye cannot see — minimal deviations, hidden patterns, and dynamics at the level of thousandths of a second.
SENTHORIS uses this data to identify objective biomarkers related to neuro-autonomic, metabolic, or toxic processes.
This is pure science — a clinically proven technology, engineering precision, and a mathematical model that transforms the smallest movements of the pupil into a reliable source of information about human health.
Accuracy Evolution
- Up to 98% accuracy and 100% specificity in controlled intoxication studies,
- 1,600+ subjects, 6,700+ measurements
- AI analysis of pupil response shows AUC ≈ 0.93,
- 92–95% overall accuracy in real-world tests
- designed to reach ≥ 95% sensitivitym,
- ≥ 97% specificity under formal medical-device validation.
Competitive Advantages
Compliance with Saudi Vision 2030 — our contribution to the national healthcare programme for prevention, digitalisation
and public safety
and public safety
-
Non-invasive rapid test15-second testing without biomaterial — a combination of speed, non-invasiveness and reliable accuracy (≥ 95%) -
Next-generation pupillometryUse of validated data and ML algorithms trained on thousands of reference reactions. Fully vertically integrated value chain – proprietary equipment for clinical research to end-to-end digital products. -
FlexibilityCompatible with 3 billion+ devices; deployable instantly via app, API, or SDK. -
Proven reaction of the pupilResearch (5,000+ tests) provides reliable correlation between pupil response and drug effects. Pilots and 1st commercial deployment in oil & gas provide practical verification and value. -
AI-second level analysisNot just automation, but "smart" diagnostics with forecasting, risk stratification, the possibility of early warning and the creation of an individual health profile. -
Edge-AI Privacy & SecurityReal-time local analysis without transmitting personal data — GDPR/HIPAA compliant. -
Partnership with a global CRO leaderDevelopment of a protocol for international multicentre clinical trials for further scaling and certification of digital products as SaMD. -
Dual Product ModelUSMC — telemedicine modules (transport, manufacturing, oil and gas, public healthcare); SENTHORIS — software, mobile AI-powered platform (B2C, B2B, B2G, SaaS, API, SDK) -
Compliance and scaleFDA / SaMD pathways — designed for international certification, global scalability — market value of $28–105 billion (2030–2038), 20% CAGR, coverage of > 3B smartphones
Vertically Integrated Technology —From Optics to AI
SENTHORIS is a fully integrated platform that combines proprietary hardware, custom software, and advanced AI analytics into a single continuum.
Our development begins with the SENTHORIS pupillometer — a precision optical instrument designed specifically for data collection in clinical and field research.
It is paired with dedicated software that ensures controlled light stimulation, accurate recording, and secure transmission of high-resolution eye data.
Our development begins with the SENTHORIS pupillometer — a precision optical instrument designed specifically for data collection in clinical and field research.
It is paired with dedicated software that ensures controlled light stimulation, accurate recording, and secure transmission of high-resolution eye data.
This foundation enables the training of our AI/ML models and validation of physiological biomarkers under strict clinical protocols.
From there, the same data architecture powers our final products — mobile applications, enterprise interfaces, SDK and API integrations — creating a seamless flow from research to real-world deployment.
Through this vertical integration, SENTHORIS maintains full control over quality, data integrity, and scalability — delivering a trusted, end-to-end ecosystem for next-generation digital diagnostics.
From there, the same data architecture powers our final products — mobile applications, enterprise interfaces, SDK and API integrations — creating a seamless flow from research to real-world deployment.
Through this vertical integration, SENTHORIS maintains full control over quality, data integrity, and scalability — delivering a trusted, end-to-end ecosystem for next-generation digital diagnostics.
Roadmap, areas of application
Detection of Narcotic Influence / current stage /
The pilot project in transport has been completed, and the first commercial deployment launched in the oil & gas sector. We are focused on real-world implementation, followed by continuous adaptation and technological evolution. Scalability readiness. SaaS / PaaS / API / SDK / SaMD
Risks of Toxic Poisoning
SENTHORIS expands pupillometry beyond narcotics to identify exposure to industrial toxins. Heavy metals and solvents alter pupil behavior — we capture and analyze these patterns. Continuous, non-invasive monitoring for workers in high-risk environments. AI for occupational safety and industrial health resilience.
Early Signs of Diabetes
Dynamic pupillometry detects early autonomic nerve dysfunction in Type II Diabetes. Even before clinical symptoms appear, pupil response shows measurable changes of 30–50%. These subtle optical markers reveal early diabetic neuropathy non-invasively. A new path to proactive diabetic care through the eyes.
Neurological Risks
SENTHORIS analyzes micro-oscillations and irregularities of the pupil response to reveal early neuro-functional disorders. From fatigue and stress to potential neurodegenerative signs — detected in seconds. A step toward digital neurology and predictive cognitive health. Where technology meets neuroscience — to protect the future.
SENTHORIS is a vertically integrated diagnostic ecosystem that transforms the pupil into a universal gateway for health and safety intelligence.
From proprietary pupillometers and specialized software for clinical research, to AI-driven analytics, mobile apps, and enterprise integrations — every layer is engineered and controlled within one continuum.
The platform detects neuro-autonomic, toxicological, and metabolic changes in under 15 seconds, without biosamples or discomfort.
It brings objective, real-time screening to workplaces, healthcare systems, and public infrastructure — creating a new layer of preventive intelligence for industrial environments, transport networks, and the cities of the future.
SENTHORIS serves three categories of users:
More than a device or an app, SENTHORIS is a living system — a connected layer of care, vigilance, and foresight embedded in the cognitive ecosystems of tomorrow.
From proprietary pupillometers and specialized software for clinical research, to AI-driven analytics, mobile apps, and enterprise integrations — every layer is engineered and controlled within one continuum.
The platform detects neuro-autonomic, toxicological, and metabolic changes in under 15 seconds, without biosamples or discomfort.
It brings objective, real-time screening to workplaces, healthcare systems, and public infrastructure — creating a new layer of preventive intelligence for industrial environments, transport networks, and the cities of the future.
SENTHORIS serves three categories of users:
- Individuals — self-checks and early risk awareness.
- Enterprises — workforce health and operational safety.
- Governments & Smart Cities — digital health monitoring at population scale.
More than a device or an app, SENTHORIS is a living system — a connected layer of care, vigilance, and foresight embedded in the cognitive ecosystems of tomorrow.
Benefits & Impact
We are pragmatic engineers. We have families and children. We have worked diligently in the hope of a better future and with the belief that we will find a new home for the project and a wise leader who will implement our plans for the benefit of nations and society.
-
Healthier nation, safer communities
Supports national prevention programs, reduces incident rates, and builds an anonymized biometric data base for early public-health insights. -
Operational safety made smart
Cuts workplace risks and HR losses through rapid AI-based screening — up to 10× cheaper than laboratory testing -
Accelerating clinical insight
Provides a validated pre-screening tool and data platform for studies on psychoactive effects, fatigue, and early disease markers. -
Prevention starts at home
Enables parents and schools to run fast, painless checks — supporting youth well-being and preventive health education. -
High-growth, evidence-driven market
Drug-screening market $28–105 B (2038, 20 % CAGR) with expansion into metabolic, neurological, and toxicology diagnostics — a long-term scalable platform.
MEET OUR TEAM
We look forward to seeing you!
Booth # 27
Booth # 27
-
Denis Zalynskiy
Engineering Heart
of the company
A leading researcher and technology innovator with extensive experience in project leadership, manufacturing facility development, and product improvement. Dedicated to driving innovation through a scientific approach.
-
Artem Karavatyi
Consulting, analytics, operations, implementation management
A seasoned international advisor guiding top-level executives across diverse enterprises. Possesses a strong strategic vision combined with a pragmatic approach to problem-solving, from initial concept development through successful implementation.
-
Dmitry Tsepkov
Head of Strategy, Business Development, and Research
A seasoned medical technology professional with a strong track record in sales, company development and international partnerships. Dedicated to identifying opportunities for collaboration that drive innovation and improve healthcare outcomes.
“
We see what the eyes can't hide. Today it detects narcotics, tomorrow — neurological disorders, diabetes, and other risks. Our goal is to make the eyes an accessible, reliable, and universal gateway for fast, non-invasive health screening
Company profile at Global Health Saudi Arabia 2025. Let's meet up!
SENTHORIS: at the right time, in the right place
The trend towards rapid growth in the adoption of digital and AI solutions, especially
for early health screening
for early health screening
- In 2025, the global digital healthcare market is estimated to be worth $387.8 billion. It is projected to grow to $2.19 trillion by 2034, with an average annual growth rate of 21.2%. The main growth is driven by investments in telemedicine, mobile applications and AI solutions, as well as demand for remote monitoring of chronic diseases.
- More than 318,000 medical applications are available for download in global app stores; in 2015, this figure was half as much.
- The global AI market in medicine in 2025 will be worth $36.96 billion, with expected growth to $613.8 billion by 2034 at a CAGR of ~37%. The fastest growing areas are diagnostics, big medical data processing and predictive analytics.
- In the US alone, the AI segment in healthtech will reach $195 billion by 2034, mainly due to accelerated digitalisation and a strict regulatory framework.
- More than half of the US population suffers from chronic diseases, creating demand for intelligent solutions for processing and storing medical data.
The global security/digital screening market (including AI diagnostics) will grow from $9.92 billion in 2025 to $13.8 billion by 2030 (CAGR 6.8%). Leading technologies — biometrics, automated recognition, non-invasive digital testing, AI/ML integration — significantly reduce the number of false alarms and accelerate throughput in mass security and medical applications.
- The growth of telemedicine — more than 25% of doctors use mobile devices to provide medical care, and 4 out of 5 use them for work tasks.
- The most sought-after areas of AI application: screening for psychoactive substances, predictive diagnosis of diabetes, neurofunctional tests, biometric processing in transport and industry.
© 2013-2025, EVERTON LTD and
3D Happy LTD group, Bulgaria
All Rights Reserved
3D Happy LTD group, Bulgaria
All Rights Reserved